Published in

Nature Research (part of Springer Nature), Nature Communications, (7), p. 12460

DOI: 10.1038/ncomms12460



Export citation

Search in Google Scholar

Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis.

Journal article published in 2016 by Solveig K. Sieberts, Jun Zhu, Niek de Vries, Jaume Bonet, Sieberts Sk, Fan Zhu, Jean-Philippe Vert, Javier García-García, Venkat S. K. Balagurusamy, Eli Stahl, Joan Planas-Iglesias, Daniel Poglayen, Manuel Alejandro Marín, Abhishek Pratap, Bharat Panwar and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO


Rheumatoid arthritis (RA) affects millions world-wide. While anti-TNF treatment is widely used to reduce disease progression, treatment fails in ∼one-third of patients. No biomarker currently exists that identifies non-responders before treatment. A rigorous community-based assessment of the utility of SNP data for predicting anti-TNF treatment efficacy in RA patients was performed in the context of a DREAM Challenge ( An open challenge framework enabled the comparative evaluation of predictions developed by 73 research groups using the most comprehensive available data and covering a wide range of state-of-the-art modelling methodologies. Despite a significant genetic heritability estimate of treatment non-response trait (h(2)=0.18, P value=0.02), no significant genetic contribution to prediction accuracy is observed. Results formally confirm the expectations of the rheumatology community that SNP information does not significantly improve predictive performance relative to standard clinical traits, thereby justifying a refocusing of future efforts on collection of other data.